GlycanLink, located in Shanghai Zhangjiang Pharmaceutical Valley, Shanghai, is a biopharmaceutical company focusing on site-specific conjugation technologies for ADCs. Founded in 2021 by Dr. Huang Wei, a researcher at the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, GlycanLink has mastered a number of site-specific conjugation technologies for ADCs with independent intellectual property rights.

GlycanLink is committed to establishing a worldwide first-class site-specific conjugated ADC service platform at home and abroad. Through technical cooperation and authorization, we hope to use our technological innovation to help our clients develop ADCs with easier manufacturing processes, more significant efficacy, and higher safety. At the same time, we attach importance to the development of pipelines with our intellectual property rights. We are currently carrying out multi-pipeline promotion, including hot targets and emerging targets, and are expected to complete IND for our first ADC within two years.